EUVIMEDEUVIMED entdecken
Open Access

Cholinergic sensing of allergen exposure by airway epithelium promotes type 2 immunity in the lungs

Ryusuke Hayashi, Yotesawee Srisomboon, Koji Iijima, Peter J Maniak, Rinna Tei, Takao Kobayashi, Mayumi Matsunaga, Huijun Luo, Mia Y Masuda, Scott M O'Grady, Hirohito Kita

Journal of Allergy and Clinical Immunology · 2024-03 · 153 (3) · 793-808.e2

DOI: 10.1016/j.jaci.2023.10.031 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2024-03. Verfasst von Ryusuke Hayashi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy, Asthma and Clinical Immunology, Mayo Clinic, Scottsdale, Ariz; Department of Medicine, Mayo Clinic, Scottsdale, Ariz. Hauptthemen laut MEDLINE: Interleukin-33, Asthma. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, Mayo Foundation for Medical Education and Research, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Nonneuronal cells, including epithelial cells, can produce acetylcholine (ACh). Muscarinic ACh receptor antagonists are used clinically to treat asthma and other medical conditions; however, knowledge regarding the roles of ACh in type 2 immunity is limited. OBJECTIVE: Our aim was to investigate the roles of epithelial ACh in allergic immune responses. METHODS: Human bronchial epithelial (HBE) cells were cultured with allergen extracts, and their ACh production and IL-33 secretion were studied in vitro. To investigate immune responses in vivo, naive BALB/c mice were treated intranasally with different muscarinic ACh receptor antagonists and then exposed intranasally to allergens. RESULTS: At steady state, HBE cells expressed cellular components necessary for ACh production, including choline acetyltransferase and organic cation transporters. Exposure to allergens caused HBE cells to rapidly release ACh into the extracellular medium. Pharmacologic or small-interfering RNA-based blocking of ACh production or autocrine action through the M3 muscarinic ACh receptors in HBE cells suppressed allergen-induced ATP release, calcium mobilization, and extracellular secretion of IL-33. When naive mice were exposed to allergens, ACh was quickly released into the airway lumen. A series of clinical M3 muscarinic ACh receptor antagonists inhibited allergen-induced IL-33 secretion and innate type 2 immune response in the mouse airways. In a preclinical murine model of asthma, an ACh receptor antagonist suppressed allergen-induced airway inflammation and airway hyperreactivity. CONCLUSIONS: ACh is released quickly by airway epithelial cells on allergen exposure, and it plays an important role in type 2 immunity. The epithelial ACh system can be considered a therapeutic target in allergic airway diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-33AsthmaMiceAnimalsHumansMice, KnockoutLungEpitheliumAcetylcholineAllergensCholinergic AgentsReceptors, Cholinergic

Stichwörter der Autor:innen

AChIL-13IL-33IL-5allergenscholine acetyltransferasegroup 2 innate lymphoid cellsmuscarinic receptor antagonists

Substanzen

Interleukin-33AcetylcholineAllergensCholinergic AgentsReceptors, Cholinergic

Autor:innen und Institutionen

  • Division of Allergy, Asthma and Clinical Immunology, Mayo Clinic, Scottsdale, Ariz; Department of Medicine, Mayo Clinic, Scottsdale, Ariz.
  • Department of Animal Science, University of Minnesota, St Paul, Minn; Department of Integrative Biology and Physiology, University of Minnesota, St Paul, Minn.
  • Mayo Clinic Graduate School of Biomedical Sciences, Rochester, Minn; Mayo Clinic Graduate School of Biomedical Sciences, Scottsdale, Ariz.
  • Division of Allergy, Asthma and Clinical Immunology, Mayo Clinic, Scottsdale, Ariz; Department of Medicine, Mayo Clinic, Scottsdale, Ariz; Department of Immunology, Mayo Clinic Rochester, Rochester, Minn; Department of…

Förderung

  • NIAID NIH HHS
  • Mayo Foundation for Medical Education and Research
  • National Institutes of Health
  • NIAID

Zitieren

APA

Hayashi, R., Srisomboon, Y., Iijima, K., Maniak, P. J., Tei, R., Kobayashi, T., Matsunaga, M., Luo, H., Masuda, M. Y., O'Grady, S. M., & Kita, H. (2024). Cholinergic sensing of allergen exposure by airway epithelium promotes type 2 immunity in the lungs. Journal of Allergy and Clinical Immunology, 153(3), 793-808.e2. https://doi.org/10.1016/j.jaci.2023.10.031

Vancouver

Hayashi R, Srisomboon Y, Iijima K, Maniak PJ, Tei R, Kobayashi T, et al. Cholinergic sensing of allergen exposure by airway epithelium promotes type 2 immunity in the lungs. Journal of Allergy and Clinical Immunology. 2024;153(3):793-808.e2. doi:10.1016/j.jaci.2023.10.031

BibTeX
@article{Hayashi2024,
  author = {Hayashi, Ryusuke and Srisomboon, Yotesawee and Iijima, Koji and Maniak, Peter J and Tei, Rinna and Kobayashi, Takao and Matsunaga, Mayumi and Luo, Huijun and Masuda, Mia Y and O'Grady, Scott M and Kita, Hirohito},
  title = {Cholinergic sensing of allergen exposure by airway epithelium promotes type 2 immunity in the lungs},
  journal = {Journal of Allergy and Clinical Immunology},
  year = {2024},
  volume = {153},
  number = {3},
  pages = {793--808.e2},
  doi = {10.1016/j.jaci.2023.10.031}
}
Kostenlos starten →